肿瘤患者使用重组人粒细胞集落刺激因子DUE标准的建立与应用

Establishment and Application of the Drug Use Evaluation Criteria on Recombinant Human Granulocyte-colony Stimulating Factor for Cancer Patients

目的:为肿瘤患者合理使用重组人粒细胞集落刺激因子(rhG-CSF)提供参考。方法:参考国内外rhG-CSF临床应用指南,结合专家咨询法,建立肿瘤患者使用rhG-CSF的药物利用评估(DUE)标准;设计患者使用rhG-CSF调查表,评价某"三甲"医院220份使用了rhG-CSF的病历资料。结果:肿瘤患者rhG-CSF的DUE标准包括用药指征、用药过程和用药结果三部分,共14条内容。运用建立的DUE标准对220份病历进行回顾性评估,结果发现该院rhG-CSF应用在符合用药指征、无禁忌证、每周至少监测2次血常规和药物相互作用方面达到了标准预期目标值,但尚存在一些不合理情况。结论:建立的肿瘤患者使用rhG-CSF DUE标准具有评价内容明确、针对性强、实用性好等优点,可为医师和临床药师开展工作提供参考。

OBJECTIVE： To provide reference for rational use of recombinant human granulocyte-colony stimulating factor （rhG-CSF） in cancer patients. METHODS： Referring to the expert advice and guideline of clinical application of rhG-CSF at home and abroad, DUE criteria on rhG-CSF for cancer patients was established; questionnaire was designed, and the medical records of rhG-CSF in a third grade class A hospital was evaluated. RESULTS： The DUE criterion on rhG-CSF for cancer patients included 3 parts, such as drug indications, the course of medication and medication results, 14 items in total. Through the implementation of DUE, retrospective evaluation of 220 medical records showed that the application of rhG-CSF was up to the standard in respects of drug indications, no contraindication, routine blood test and drug interaction monitoring at least twice every week, there still was irrational phenomenon. CONCLUSIONS： The established DUE criterion on rhG-CSF for cancer patients is with the characteristics of definite content, target and paracticabilitg, which can provide reference for the work development of clinical pharmacists.